AI and Real-World Data Are Turning the Promise of Precision Medicine into Clinical Reality
核心洞察
Precision medicine market valued at USD 118.69 billion in 2025 is projected to reach USD 544.26 billion by 2035, growing at a CAGR of 16.45%.
AI-enabled real-world data from EHRs, claims, and wearables is overcoming traditional clinical trial limitations by capturing diverse patient experiences over time.
Integration of genomic data with RWD is enabling molecular profiling and targeted therapies, particularly in oncology for breast, lung, and colorectal cancers.
The long-anticipated promise of precision medicine—healthcare tailored to an individual's genes, lifestyle, and disease characteristics—is finally moving from aspiration toward clinical reality, propelled by the convergence of artificial intelligence, real-world data, and genomic insights. The global precision medicine market, valued at USD 118.69 billion in 2025, is projected to reach USD 544.26 billion by 2035, expanding at a compound annual growth rate of 16.45%, according to market analysis from SNS Insider.
The concept of personalized care has deep historical roots, dating to Hippocrates, who championed understanding the individual over just the disease. Yet it was the completion of human genome mapping in 2003 that truly opened the door to therapies beyond the traditional one-size-fits-all approach. The 2015 Precision Medicine Initiative formalized a U.S. effort to develop treatments tailored to variability in genes, environment, and lifestyle. Despite these advances, widespread adoption has been hampered by a lack of diverse genetic data, high testing costs, and persistent privacy and technical challenges.
The Data Gap That Held Precision Medicine Back
A fundamental obstacle has been the limited nature of medical data tied to individual patient characteristics. Randomized controlled trials, while the gold standard of medical research, have inherent shortcomings. "Recruiting and retaining patients is difficult, and necessary exclusions for safety and reducing confounding factors lead to trial populations that are healthier and less diverse than society at large," notes Sujay Jadhav, CEO at Verana Health, writing for Forbes. The limited duration of trials can also hinder detection of long-term effects, rendering an incomplete picture of how diseases and treatments affect specific patient groups.
How Real-World Data Is Filling the Void
Real-world data—encompassing electronic health records, medical claims, disease registries, and wearable devices—offers a richer, more representative supply of information reflecting the population at large over extended periods. However, harnessing this data has historically proven difficult. Clinician notes in EHRs, while rich with information, are not standardized or easily searchable.
"Prior to advanced AI, this simply wasn't feasible," Jadhav explains. Now, multidisciplinary teams use advanced AI tools and large language models to curate disease-specific datasets capturing the experiences of millions of patients over time. These resources give researchers and clinicians real-world insights into diseases and treatment responses, helping fill data gaps and deepen understanding of disease progression and outcomes in representative populations.
Genomic Integration and Targeted Therapies
A critical advance is the integration of genomic data with real-world data to enable molecular profiling and targeted therapies. Using AI analytics, researchers can better understand correlations between molecular biomarkers, treatment decisions, and clinical outcomes. In oncology, tumor markers provide the molecular footprint, and the combination of RWD and genomic data is driving insight to guide targeted therapies for breast, lung, and colorectal cancers—for example, HER2 inhibitors (搜索) for breast cancer (搜索).
AI-driven tests leveraging RWD also show potential for faster, lower-cost assessment of cancer recurrence risk compared to gene-expression testing, helping address the high cost barrier that has limited access to genetic testing.
Industry Leaders Driving Innovation
Companies like Illumina are at the forefront, with advanced next-generation sequencing platforms enabling genomic testing for oncology, rare diseases, reproductive health, and population genomics. The company has become a critical partner to hospitals, research institutions, and pharmaceutical companies developing personalized therapies through ongoing innovation in sequencing accuracy, speed, and cost.
The broader industry is also being shaped by the increasing adoption of AI-assisted diagnostics, companion diagnostics, and CRISPR technologies. North America is expected to continue dominating the precision medicine market due to high investments in genomic research and developed healthcare infrastructure, while Asia Pacific is projected to witness the highest growth rate, driven by government healthcare initiatives and growing genomic testing programs.
Challenges and the Road Ahead
These tools are not without risk. AI-enabled RWD is only as strong as the data behind it, and gaps in representation can reinforce inequities if certain populations are underrepresented or inaccurately captured. "Unstructured clinical notes, claims data and EHRs can also reflect inconsistent documentation, missing context and historical bias, creating the potential for flawed insights without careful curation and clinical validation," Jadhav cautions.
Industry leaders must address transparency, privacy, and trust. Strong governance, human clinical oversight, and clear validation standards will be essential to ensure these tools enhance medical decision-making without replacing physician judgment.
In pharmacogenomics, understanding how genes affect drug efficacy is already helping doctors prescribe the right drug at the optimal dose while reducing adverse reactions. Rare diseases, affecting 25 to 30 million Americans, have long lacked effective treatments, but genetic sequencing, AI, and RWD are now supporting diagnosis and the development of targeted therapies for these conditions.
The future of precision medicine will be driven by advances in genomics, artificial intelligence, molecular diagnostics, and personalized therapeutics. As precision medicine becomes further integrated into mainstream healthcare, it will continue to transform how disease is diagnosed, how treatment is chosen, and how patients fare long-term across the globe.